Potent Molecular-targeted Therapies for Gastro-entero-pancreatic Neuroendocrine Carcinoma

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2023 Jul 8

PMID 37422534

Authors

Akira Ooki

Hiroki Osumi

Koshiro Fukuda

Kensei Yamaguchi

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine differentiation, can arise in various organs. NENs have been divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, each of which has a distinct etiology, molecular profile, and clinicopathological features. While the majority of NECs originate in the pulmonary organs, extrapulmonary NECs occur most predominantly in the gastro-entero-pancreatic (GEP) system. Although platinum-based chemotherapy is the main therapeutic option for recurrent or metastatic GEP-NEC patients, the clinical benefits are limited and associated with a poor prognosis, indicating the clinically urgent need for effective therapeutic agents. The clinical development of molecular-targeted therapies has been hampered due to the rarity of GEP-NECs and the paucity of knowledge on their biology. In this review, we summarize the biology, current treatments, and molecular profiles of GEP-NECs based on the findings of pivotal comprehensive molecular analyses; we also highlight potent therapeutic targets for future precision medicine based on the most recent results of clinical trials.

Citing Articles

Treatment and management of duodenal gangliocytic paraganglioma: A case report.

Xiao N, Zhu S, Liu H, Li L, Shi L Exp Ther Med. 2024; 28(6):435.

PMID: 39355522 PMC: 11443592. DOI: 10.3892/etm.2024.12723.

An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.

Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M Int J Mol Sci. 2024; 25(16).

PMID: 39201255 PMC: 11354135. DOI: 10.3390/ijms25168568.

Clinicopathologic and molecular characteristics of neuroendocrine carcinomas of the gallbladder.

Tang H, Jiang X, Zhu L, Xu L, Wang X, Li H Histol Histopathol. 2024; 40(3):389-400.

PMID: 39041213 DOI: 10.14670/HH-18-788.

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study.

Niu X, Sun S, Fan W, Yue P, Yao W, Wang Y PLoS One. 2024; 19(6):e0303440.

PMID: 38837985 PMC: 11152281. DOI: 10.1371/journal.pone.0303440.

Neuroendocrine Neoplasia: From Pathophysiology to Novel Therapeutic Approaches.

Carsote M, Nistor C Biomedicines. 2024; 12(4).

PMID: 38672156 PMC: 11048153. DOI: 10.3390/biomedicines12040801.

References

Wang J, Huang S, Marzese D, Hsu S, Kawas N, Chong K . Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol. 2014; 135(2):532-541. PMC: 4307785. DOI: 10.1038/jid.2014.418. View

Walenkamp A, Sonke G, Sleijfer D . Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2008; 35(3):228-36. DOI: 10.1016/j.ctrv.2008.10.007. View

Sen T, Tong P, Stewart C, Cristea S, Valliani A, Shames D . CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017; 77(14):3870-3884. PMC: 5563854. DOI: 10.1158/0008-5472.CAN-16-3409. View

Ishida M, Sekine S, Taniguchi H, Fukagawa T, Katai H, Kushima R . Consistent absence of HER2 expression, regardless of HER2 amplification status, in neuroendocrine carcinomas of the stomach. Histopathology. 2013; 64(7):1027-31. DOI: 10.1111/his.12348. View

Sorbye H, Kong G, Grozinsky-Glasberg S . PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2019; 27(3):R67-R77. DOI: 10.1530/ERC-19-0400. View

Konukiewitz B, Schlitter A, Jesinghaus M, Pfister D, Steiger K, Segler A . Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol. 2017; 30(4):587-598. DOI: 10.1038/modpathol.2016.217. View

Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K . Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014; 105(9):1176-81. PMC: 4462387. DOI: 10.1111/cas.12473. View

Stelwagen J, de Vries E, Walenkamp A . Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review. JAMA Oncol. 2021; 7(5):759-770. DOI: 10.1001/jamaoncol.2020.8072. View

Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A . Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2016; 23(2):600-609. PMC: 6560642. DOI: 10.1158/1078-0432.CCR-16-1113. View

10.

Groelly F, Fawkes M, Dagg R, Blackford A, Tarsounas M . Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2022; 23(2):78-94. DOI: 10.1038/s41568-022-00535-5. View

11.

Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P . Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017; 543(7643):65-71. DOI: 10.1038/nature21063. View

12.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

13.

Lallo A, Frese K, Morrow C, Sloane R, Gulati S, Schenk M . The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clin Cancer Res. 2018; 24(20):5153-5164. DOI: 10.1158/1078-0432.CCR-17-2805. View

14.

Chan D, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W . Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022; 169:74-81. DOI: 10.1016/j.ejca.2022.03.029. View

15.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

16.

Byers L, Wang J, Nilsson M, Fujimoto J, Saintigny P, Yordy J . Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2(9):798-811. PMC: 3567922. DOI: 10.1158/2159-8290.CD-12-0112. View

17.

Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G . Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018; 37(3):222-229. PMC: 6338394. DOI: 10.1200/JCO.18.00264. View

18.

Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A . A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial). Neuroendocrinology. 2020; 110(11-12):988-993. DOI: 10.1159/000505550. View

19.

Ooki A, Shinozaki E, Yamaguchi K . Immunotherapy in Colorectal Cancer: Current and Future Strategies. J Anus Rectum Colon. 2021; 5(1):11-24. PMC: 7843143. DOI: 10.23922/jarc.2020-064. View

20.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View